StemRIM Inc. (JP:4599)
:4599
Want to see JP:4599 full AI Analyst Report?
Top Page
StemRIM Inc.
(4599)
Select Model
Select Model
Rating:49Neutral
Price Target:
¥319.00
▲(25.10% Upside)
Action:Reiterated
Date:06/19/26
The score is held down primarily by unstable fundamentals: revenue has disappeared in recent years, losses are large, and cash flow is materially negative, despite low leverage. Technicals provide some support with the price trading above major moving averages, but valuation remains unfavorable due to ongoing losses and no dividend yield data.
Positive Factors
Very low leverage / financial flexibility
Near-zero debt is a durable strength for a biotech with long development cycles: it lowers default risk, reduces fixed financing costs, and preserves optionality to raise or deploy capital when needed. This structural flexibility supports funding R&D or partnering without immediate solvency pressure.
Negative Factors
Revenue collapsed to zero
A structural disappearance of revenue undermines business sustainability: it implies loss of recurring licensing or product income, eliminates internal funding for R&D, raises dependency on external financing, and reduces visibility for multi-quarter planning—key risks for a developmental biotech.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / financial flexibility
Near-zero debt is a durable strength for a biotech with long development cycles: it lowers default risk, reduces fixed financing costs, and preserves optionality to raise or deploy capital when needed. This structural flexibility supports funding R&D or partnering without immediate solvency pressure.
Read all positive factors
StemRIM Inc. (4599) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥18.80B
Dividend YieldN/A
Average Volume (3M)122.86K
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue GrowthN/A
EPS Growth6.10%
CountryJP
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-31.14
Shares Outstanding62,681,200
10 Day Avg. Volume118,910
30 Day Avg. Volume122,863
Financial Highlights & Ratios
PEG Ratio1.85
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-13.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-30.8
Revenue Forecast (FY)N/A
StemRIM Inc. Business Overview & Revenue Model
Company Description
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently under...
How the Company Makes Money
StemRIM Inc. generates revenue primarily through licensing its proprietary technologies to pharmaceutical and biotechnology companies. Additionally, it earns income from collaboration agreements, research funding, and development milestone payment...
StemRIM Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
72
Positive
Cash Flow
30
Negative
| Breakdown | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 2.35B | 22.98M | 1.40B |
| Gross Profit | -49.50M | -44.35M | 2.30B | 22.98M | 1.40B |
| EBITDA | -1.92B | -2.03B | 190.18M | -1.93B | -550.13M |
| Net Income | -1.93B | -2.02B | 168.35M | -1.95B | -582.45M |
Balance Sheet | |||||
| Total Assets | 7.52B | 9.09B | 10.72B | 9.61B | 10.93B |
| Cash, Cash Equivalents and Short-Term Investments | 6.99B | 8.41B | 10.22B | 8.88B | 10.17B |
| Total Debt | 0.00 | 0.00 | 531.00K | 3.67M | 6.73M |
| Total Liabilities | 210.27M | 194.06M | 348.51M | 207.74M | 231.10M |
| Stockholders Equity | 7.31B | 8.89B | 10.37B | 9.40B | 10.70B |
Cash Flow | |||||
| Free Cash Flow | -1.46B | -1.88B | 1.14B | -1.40B | -608.70M |
| Operating Cash Flow | -1.41B | -1.88B | 1.14B | -1.40B | -519.65M |
| Investing Cash Flow | -42.50M | -4.78M | -344.00K | -330.00K | -92.72M |
| Financing Cash Flow | 41.25M | 78.97M | 202.60M | 112.86M | 109.32M |
StemRIM Inc. Technical Analysis
Positive
255.00
Price Trends
299.18
Positive
297.64
Positive
291.01
Positive
Market Momentum
0.66
Negative
53.13
Neutral
77.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4599, the sentiment is Positive. The current price of 255 is below the 20-day moving average (MA) of 290.55, below the 50-day MA of 299.18, and below the 200-day MA of 291.01, indicating a bullish trend. The MACD of 0.66 indicates Negative momentum. The RSI at 53.13 is Neutral, neither overbought nor oversold. The STOCH value of 77.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4599.
StemRIM Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥6.23B | 86.18 | ― | 1.24% | -7.13% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥25.67B | -35.15 | ― | ― | -11.11% | -187.80% | |
49 Neutral | ¥18.80B | -10.30 | ― | ― | ― | 6.10% | |
43 Neutral | ¥34.83B | -10.64 | ― | ― | -87.41% | 43.60% | |
42 Neutral | ¥12.35B | -20.34 | ― | ― | -25.02% | -697.06% | |
42 Neutral | ¥8.22B | -8.45 | ― | ― | -62.06% | 7.56% |
* Healthcare Sector Average
JP:4599
StemRIM Inc.
300.00
-22.00
-6.83%
JP:4593
Healios KK
258.00
-161.00
-38.42%
JP:4880
CellSource Co., Ltd.
314.00
-369.14
-54.04%
JP:4978
ReproCELL Inc.
126.00
-43.00
-25.44%
JP:7774
Japan Tissue Engineering Co., Ltd.
632.00
27.00
4.46%
JP:7776
CellSeed Inc.
210.00
-277.00
-56.88%
StemRIM Inc. Corporate Events
StemRIM to Record AMED Subsidy as Non-Operating Income for Gene Therapy Project
Jun 19, 2026
StemRIM Inc. said it will book non-operating income in the fourth quarter of the fiscal year ending July 31, 2026, after a subsidy for its regenerative medicine project was finalized. The company has secured 59.973 million yen in subsidy income fo...
StemRIM Wins Australian Patent for Redasemtide Cartilage Disorder Therapy
Jun 17, 2026
StemRIM Inc. has secured imminent patent registration in Australia for the use of its HMGB1 fragment peptide drug candidate Redasemtide as a therapeutic agent for cartilage disorders, including traumatic cartilage defects of the joint, osteoarthri...
StemRIM Wins Russian Patent to Expand Redasemtide Use in Fatty Liver and NASH
Jun 16, 2026
StemRIM Inc. has announced that a medical use patent for its regeneration-inducing drug candidate Redasemtide, covering a new therapeutic indication for fatty liver and non-alcoholic steatohepatitis, will soon be registered in Russia. The patent, ...
StemRIM posts continued loss but secures R&D runway through 2028
Jun 10, 2026
StemRIM Inc. reported a net loss of ¥1.41 billion for the nine months ended April 30, 2026, slightly improving from the previous year’s loss, with no operating revenue booked and basic earnings per share at a loss of ¥22.51. Total ...
StemRIM Plans Tax-Efficient Capital Reduction Ahead of July Extraordinary Meeting
May 13, 2026
StemRIM Inc. has set June 1, 2026 as the record date for shareholders eligible to vote at an extraordinary general meeting scheduled for July 29, 2026 in Osaka. The sole agenda item will be a proposed reduction of the company’s stated capita...
StemRIM Highlights Shionogi’s Timelines for Regenerative Drug Redasemtide in DEB and Stroke
May 12, 2026
StemRIM said partner Shionogi has set out an updated clinical and commercialization timeline for Redasemtide, a peptide drug derived from HMGB1 and licensed from StemRIM as a flagship “Regeneration-Inducing Medicine”. Shionogi is runni...
StemRIM Completes Enrollment in Early-Stage Redasemtide Trial for Ischemic Cardiomyopathy
Apr 15, 2026
StemRIM Inc. said it has completed patient enrollment in a Phase 1/2 investigator-initiated clinical trial of its regeneration-inducing drug candidate redasemtide in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.